Final data from the phase ib study of acelarin plus cisplatin in patients with advanced biliary tract cancer published online ahead of print in the oncologist

Acelarin plus cisplatin's high objective response rate and favorable safety profile confirmed

NCNA Ratings Summary

NCNA Quant Ranking